Literature DB >> 2979715

Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes.

J Uetrecht1, N Zahid, R Rubin.   

Abstract

The chronic use of procainamide is associated with a high incidence of drug-induced lupus and also agranulocytosis. We have previously demonstrated that procainamide is metabolized in the liver to reactive hydroxylamine (PAHA) and nitroso (nitroso-PA) metabolites which covalently bind to protein and are toxic to lymphocytes. We proposed that these metabolites were responsible for the toxicities of procainamide. However, PAHA and nitroso-PA do not appear to escape the liver in significant concentrations. In this paper we describe the metabolism of procainamide to a reactive hydroxylamine by neutrophils and mononuclear leukocytes. Such metabolism only occurs if the cells have been stimulated to have a respiratory burst. These observations have obvious possible implications for the mechanism of procainamide-induced agranulocytosis (formation of a reactive metabolite by neutrophils) and procainamide-induced lupus (formation of a reactive metabolite by monocytes). The metabolism of drugs to reactive metabolites by monocytes may be a general mechanism for hypersensitivity reactions because monocytes play a key role in the processing of antigen and stimulation of antibody synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979715     DOI: 10.1021/tx00001a013

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  13 in total

Review 1.  Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.

Authors:  J P Uetrecht
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

Review 2.  Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes.

Authors:  J P Uetrecht
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

Review 3.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

4.  Metabolomics reveals the metabolic map of procainamide in humans and mice.

Authors:  Fei Li; Andrew D Patterson; Kristopher W Krausz; Bernhard Dick; Felix J Frey; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2012-02-24       Impact factor: 5.858

5.  Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro.

Authors:  R L Rubin; J T Curnutte
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 6.  Idiosyncratic Drug Reactions: A 35-Year Chemical Research in Toxicology Perspective.

Authors:  Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2022-06-10       Impact factor: 3.973

7.  Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes.

Authors:  C Goebel; M Kubicka-Muranyi; T Tonn; J Gonzalez; E Gleichmann
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.

Authors:  Arno G Siraki; Leesa J Deterding; Marcelo G Bonini; Jinjie Jiang; Marilyn Ehrenshaft; Kenneth B Tomer; Ronald P Mason
Journal:  Chem Res Toxicol       Date:  2008-05-19       Impact factor: 3.739

9.  Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases.

Authors:  R Loebstein; O Diav-Citrin; G Atanackovic; N F Olivieri; G Koren
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

10.  Prevention of benzene-induced myelotoxicity by nonsteroidal anti-inflammatory drugs.

Authors:  G F Kalf; M J Schlosser; J F Renz; S J Pirozzi
Journal:  Environ Health Perspect       Date:  1989-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.